enGene Inc. Common Stock (ENGN)
4.00
-0.03 (-0.74%)
At close: Apr 10, 2025, 3:59 PM
4.00
0.02%
After-hours: Apr 10, 2025, 04:14 PM EDT
-0.74% (1D)
| Bid | 4 |
| Market Cap | 203.91M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -69.05M |
| EPS (ttm) | -1.48 |
| PE Ratio (ttm) | -2.7 |
| Forward PE | -3.45 |
| Analyst | Buy |
| Ask | 4.25 |
| Volume | 132,640 |
| Avg. Volume (20D) | 85,950 |
| Open | 4.04 |
| Previous Close | 4.03 |
| Day's Range | 3.50 - 4.03 |
| 52-Week Range | 3.50 - 16.62 |
| Beta | -0.37 |
About ENGN
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calm...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 1, 2022
Employees 56
Stock Exchange NASDAQ
Ticker Symbol ENGN
Website https://www.engene.com
Analyst Forecast
According to 9 analyst ratings, the average rating for ENGN stock is "Buy." The 12-month stock price forecast is $28, which is an increase of 600.00% from the latest price.
Stock Forecasts1 month ago
+1.19%
EnGene Holdings shares are trading higher after Pi...
Unlock content with
Pro Subscription
5 months ago
+1.91%
EnGene Holdings shares are trading higher. The company announced it generated approximately $60 million in proceeds from a private placement.
